Page 1 |
Save page Remove page | Previous | 1 of 169 | Next |
|
small (250x250 max)
medium (500x500 max)
large ( > 500x500)
Full Resolution
All (PDF)
|
This page
All
Subset |
ANIMAL TO HUMAN SCALING
AND PHARMACOKINETIC/PHARMACODYNAMIC MODELING
OF ANTICANCER DRUGS
by
Joy C. Hsu
A Dissertation Presented to the
FACULTY OF THE GRADUATE SCHOOL
UNIVERSITY OF SOUTHERN CALIFORNIA
In Partial Fulfillment of the
Requirements for the Degree
DOCTOR OF PHILOSOPHY
(BIOMEDICAL ENGINEERING)
May 2009
Copyright 2009 Joy C. Hsu
Object Description
| Title | Animal to human scaling and pharmacokinetic/pharmacodynamic modeling of anticancer drugs |
| Author | Hsu, Joy C. |
| Author email | joy.c.hsu@gmail.com; joy_2000@alum.berkeley.edu |
| Degree | Doctor of Philosophy |
| Document type | Dissertation |
| Degree program | Biomedical Engineering |
| School | Viterbi School of Engineering |
| Date defended/completed | 2008-12-18 |
| Date submitted | 2009 |
| Restricted until | Unrestricted |
| Date published | 2009-03-24 |
| Advisor (committee chair) | D'Argenio, David Z. |
| Advisor (committee member) |
Khoo, Michael C. K. Schumitzky, Alan |
| Abstract | Three major interspecies scaling approaches are analyzed and the predictive performance for each of these scaling methods in estimating human systemic clearance, volume of distribution at steady state, and plasma concentration-time profile are evaluated. The three interspecies scaling methods analyzed in this work are allometric scaling, physiologically based pharmacokinetic (PBPK) model scaling, and the population compartmental model scaling. Based on the results for 17-[[(2-dimethylamino)-ethyl]amino]geldanamycin (17DMAG, a geldanamycin derivative), allometric scaling provides the poorest human estimations. Even with different correction factors, allometric scaling cannot consistently provide reliable human PK parameter estimates. However, both the whole body PBPK scale-up approach and the population compartmental model scaling approach perform fairly well in estimating human plasma concentration-time profiles and human PK parameters for 17DMAG. Overall, the population compartmental scaling approach performs slightly better than the whole body PBPK scale-up approach. Most important of all, results from both of these scaling approaches suggests that metabolism in liver for 17DMAG should be scaled to account for metabolic size dependency.; Pharmacokinetic-tumor pharmacodynamic models are developed for 17DMAG and 17-(allylamino)-17-demethoxygeldanamycin (17AAG, also a geldanamycin derivative). The PK-tumor PD models developed for both 17DMAG and 17AAG are able to provide good estimations for the plasma and tumor concentration-time profiles. Based on this analysis, indirect response models are also able to provide good estimations for onco-proteins Raf-1 and HER-2 for 17DMAG and 17AAG. For heat shock proteins HSP70 and HSP90, results from this analysis suggest that the feedback autoregulatory mechanism plays a crucial role in regulating the PD responses for HSPs for both 17DMAG and 17AAG. Given the feedback modeling approaches considered, only the mechanistically based feedback model is able to describe the large induction observed in HSP70 and HSP90 responses for 17AAG. However, results also suggest that the mechanistically based feedback model used to describe HSP70 and HSP90 responses for 17AAG may not be identifiable.; Population analysis of 17DMAG Phase I clinical trial data is also performed. Different covariates are analyzed, and results from the population analysis for 17DMAG suggest that none of the covariates can explain the inter-individual variabilities in the PK parameters for the population PK model. |
| Keyword | interspecies scaling; allometric scaling; physiologically based pharmacokinetic (PBPK) model scaling; population compartmental model scaling; pharmacokinetic-tumor pharmacodynamic modeling; indirect response models; feedback autoregulatory models; population pharmacokinetic analysis |
| Language | English |
| Part of collection | University of Southern California dissertations and theses |
| Publisher (of the original version) | University of Southern California |
| Place of publication (of the original version) | Los Angeles, California |
| Publisher (of the digital version) | University of Southern California. Libraries |
| Provenance | Electronically uploaded by the author |
| Type | texts |
| Legacy record ID | usctheses-m2034 |
| Rights | Hsu, Joy C. |
| Repository name | Libraries, University of Southern California |
| Repository address | Los Angeles, California |
| Repository email | http://www.usc.edu/isd/libraries/services/ask_a_librarian/email/ |
| Filename | etd-Hsu-2618 |
| Archival file | uscthesesreloadpub_Volume26/etd-Hsu-2618.pdf |
Description
| Title | Page 1 |
| Full text | ANIMAL TO HUMAN SCALING AND PHARMACOKINETIC/PHARMACODYNAMIC MODELING OF ANTICANCER DRUGS by Joy C. Hsu A Dissertation Presented to the FACULTY OF THE GRADUATE SCHOOL UNIVERSITY OF SOUTHERN CALIFORNIA In Partial Fulfillment of the Requirements for the Degree DOCTOR OF PHILOSOPHY (BIOMEDICAL ENGINEERING) May 2009 Copyright 2009 Joy C. Hsu |
Comments
Post a Comment for Page 1
